Randomized Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients To compare progression free survival (PFS) as determined by Blinded Independent Committee Review and overall survival (OS) of nivolumab combined with ipilimumab to pemetrexed plus cisplatin or carbopl...

• Country None
• organs None
• Specialty None

A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy Treated Non-Small Cell Lung Cancer Patients Estudio Fase II doble ciego, aleatorizado, de grupos paralelos, de BMS-690514 frente a erlotinib en pacientes con cáncer de pulmón no microcítico previamente tratados con quimioterapia. Revised Protocol Number 01, incorporating amendment 03 + Pharmacogenetics Blood Sample Amendment 01 (version 1.0 dated 30-Jul-08) + Protocol Amendment 02 FDG-PET Sub-Study (version 1.0 dated 19-Sep-08) To compare the Progression-free survival (PFS) in subjects receiving BMS-690514 relative to erlotinib.

• Country None
• organs None
• Specialty None

A Phase 2 Randomized, Double Blinded (BMS-562247 and enoxaparin), Active-Controlled (enoxaparin and warfarin), Parallel-Arm, Dose Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery To determine the dose-response relationship among the three QD and three BID doses of oral BMS-562247 on the composite endpoint of adjudicated VTE events (asymptomatic and symptomatic DVT and non-fata...

• Country None
• organs None
• Specialty None

A trial to determine the clinical benefit of administering Nivolumab in patients with advanced cancer and/or cancer that has spread to other sites in the body To evaluate the clinical benefit rate at week 16 (CBR16) of Nivolumab monotherapy on advanced malignancies of multiple types of cancer

• Country None
• organs None
• Specialty None

An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and Raltegravir Twice Daily or to a Regimen of Atazanavir/Ritonavir Once Daily and Tenofovir/Emtricitabine Once Daily in Virologically Suppressed HIV-1 Infected Subjects With Safety and/or Tolerability Issues on their Present Treatment Regimen (the HARNESS study) The primary objective of this study is to estimate the proportion of subjects with HIV 1 RNA < 40 c/mL through 24 weeks, following a switch due to treatment related safety and/or tolerability issues, ...

• Country None
• organs None
• Specialty None

An international study at different study sites testing the safety and effectiveness of a drug called BMS-986141 to prevent recurrence of brain infarction in patients receiving acetylsalicylic acid (ASA) following Acute Ischemic Stroke or Transient Ischemic Attack Estudio internacional en diferentes centros para evaluar la seguridad y eficacia de un medicamento llamado BMS-986141 para prevenir la recurrencia de infarto cerebral en pacientes que reciben ácido acetilsalicílico (AAS), después de un ictus isquémico agudo o de un accidente isquémico transitorio To determine the dose-response relationship of BMS-986141 on the recurrence of brain infarction at 28 days as assessed by a composite of symptomatic stroke and unrecognized brain infarction as assesse...

• Country None
• organs None
• Specialty None

A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 1.0, dated 30-Mar-06, and Pharmacogenomics Tissue Sample Amendment Number 02 - Site Specific, version 1.0, dated 12-Apr-06 To assess efficacy of BMS-275183 in pretreated NSCLC patients as measured by the tumor response rate according to the SWOG criteria.

• Country None
• organs None
• Specialty None

Safety and Efficacy study of ipilimumab 3 mg/kg versus ipilimumab 10 mg/kg in subjects with metastatic castration resistant prostate cancer who are chemotherapy naive Estudio de eficacia y seguridad de 3 mg/kg frente a 10 mg/kg en sujetos adultos con cáncer de próstata metastásico resistente a la castración no tratados previamente con quimioterapia The purpose of this study is to examine the safety and effectiveness (how well the drug works) of two different doses ( 3 mg/kg and 10 mg/kg) of ipilimumab (Yervoy?) in patients with metastatic castra...

• Country None
• organs None
• Specialty None

HIV-1 Attachment Inhibitor comparison in Heavily Treatment Experienced patients The purpose of this study is to compare the efficacy of BMS-663068 relative to placebo, when given on the background of a failing regimen, by determining the mean change in log10 HIV-1 RNA from Day 1 ...

• Country None
• organs None
• Specialty None

Trial of Elotuzumab/Thalidomide/dexamethasone in subjects with Relapsed and/or Refractory Multiple Myeloma Estudio de elotuzumab/talidomida/dexametasona en sujetos con mieloma múltiple en recidiva y/o resistente al tratamiento To determine the safety and tolerability of Thalidomide-dexamethasone-Elotuzumab (TdE) in subjects with relapsed and/or refractory MM as assessed by the incidence of severe (Grade 3 or higher) non-hem...

• Country None
• organs None
• Specialty None